-
Mashup Score: 62Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma - 9 day(s) ago
PURPOSE Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71). Targeted DNA sequencing of PBSC products performed for CH-associated or myeloid malignancy-associated genes identified pathogenic mutations in these patients. RESULTS CH was identified in the PBSC product of 46 patients (14.3%) with most prominent representation of DNMT3A (n = 25), PPM1D (n = 7), TET2 (n = 7), and TP53 (n = 5) mutations. Presence of CH in the PBSC product was an independent predictor of t-MN (adjusted hazard ratio [aHR],
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 96Genentech: Press Releases | Sunday, Apr 14, 2024 - 14 day(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31
Introduction Cancer-related cognitive impairment is common among people diagnosed with and treated for cancer. This can be a distressing and disabling side effect for impacted individuals. Interventions to mitigate cognitive dysfunction are available, but, to date, most have been trialled in samples that are largely or exclusively composed of people with solid tumours. Intervention strategies to support cognitive functioning are needed, but there is a paucity of research in this area. The main aim of this study is to test the feasibility and acceptability of methods and procedures intended for use in a definitive trial of a web-based cognitive rehabilitation programme, Responding to Cognitive Concerns (eReCog), in people who have received chemotherapy for aggressive lymphoma. Methods and analysis The proposed study is a single-site, parallel-group, pilot randomised controlled trial, with one baseline and one follow-up (or postintervention) assessment. 38 people from the target populati
Source: bmjopen.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma - 15 day(s) ago
PURPOSE Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71). Targeted DNA sequencing of PBSC products performed for CH-associated or myeloid malignancy-associated genes identified pathogenic mutations in these patients. RESULTS CH was identified in the PBSC product of 46 patients (14.3%) with most prominent representation of DNMT3A (n = 25), PPM1D (n = 7), TET2 (n = 7), and TP53 (n = 5) mutations. Presence of CH in the PBSC product was an independent predictor of t-MN (adjusted hazard ratio [aHR],
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 70Primary Large B-cell Lymphomas of Immune-Privileged Sites - 16 day(s) ago
Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinic
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68Primary Large B-cell Lymphomas of Immune-Privileged Sites - 17 day(s) ago
Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinic
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma - 17 day(s) ago
PURPOSE Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71). Targeted DNA sequencing of PBSC products performed for CH-associated or myeloid malignancy-associated genes identified pathogenic mutations in these patients. RESULTS CH was identified in the PBSC product of 46 patients (14.3%) with most prominent representation of DNMT3A (n = 25), PPM1D (n = 7), TET2 (n = 7), and TP53 (n = 5) mutations. Presence of CH in the PBSC product was an independent predictor of t-MN (adjusted hazard ratio [aHR],
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia - 18 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
Risk of therapy related myeloid neoplasms (tMN) after ASCT for Hodgkin • 321 pts • clonal haematopoiesis in PBSC prod: 14% • TP53 and / or PPM1D mutation ⬆️ risk tMN (HR 7.3) • DNMT3a alone did NOT ⬆️ risk Worth avoiding in high risk pts? #lymsm https://t.co/a3jP1ddAas